Neozyme International, Inc. Announces Successful Increase in Dissolved Oxygen in Leachate From Major Landfill Site in Pennsylvan

Neozyme International, Inc. Announces Successful Increase in Dissolved Oxygen in
Leachate From Major Landfill Site in Pennsylvania 


ALISO VIEJO, Calif., Nov. 11  /PRNewswire/ -- Neozyme International, Inc.
(Neozyme), a subsidiary of International Daleco Corporation (Pink Sheets: ILDO),
is pleased to announce the successful increase in dissolved oxygen (DO) in a
packed bed reactor site.  The reactor treats leachate from a major landfill
facility in Pennsylvania.  The site is receiving twice the organic load it was
designed for and has been unable to reduce the organic load required by a county
wastewater treatment plant.  The plant and discharge lines have heavy hydrogen
sulfide gases.  By adding Neozyme's bio-organic catalyst, the organic discharge
was reduced 60%, the hydrogen sulfide gases were substantially reduced and the
DO was increased fourfold in ten days.  Eighty-two percent of all U.S. municipal
solid waste (roughly 134 million tons annually) ends up in the nation's more
than 7,500 landfills.

The ability to non-mechanically increase DO, with just parts per million of our
liquid catalyst, is a major breakthrough of Neozyme's patented bio-organic
technology.  By increasing the DO, organic loads can be quickly reduced in any
body of water, whether it is a municipal wastewater plant, industrial treatment
plant, lake, river or ocean.

Neozyme manufactures and sells its patented line of bio-organic catalytic
formulations for numerous markets including, but not limited to, municipal
wastewater treatment, commercial/industrial, hydrocarbon remediation, industrial
metal cleaning and agriculture.  All Neozyme products are non-toxic, 100%
biodegradable and can be safely used around humans, animals, marine life,
vegetation and the environment.  No special clothing or handling apparatus is
required.  For more information, please visit http://www.daleco.com/ .

This News Release contains certain forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934.  These forward-looking statements are based largely on the
Company's expectations of forecasts of future events, can be affected by
inaccurate assumptions and are subject to various risks and known and unknown
uncertainties, a number of which are beyond the Company's control. Therefore,
actual results could differ materially from the forward-looking statements
herein. 

DATASOURCE: Neozyme International, Inc.



CONTACT:  Parker Dale, Chairman of International Daleco Corporation,

[phone], or fax, [phone], or email,  



Web site:  http://www.daleco.com/ 

Copyright